Audit: QRS - Shatavari for Health & Longevity

Audit conducted on 21/08/2026 03:34 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every protocol value, tier item, gate item, biomarker row and cadence string traces to a named ER passage (ER 384–404, 441, 473–492, 334–360, 156–232, 262–310).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	action_3_sub keeps “No study of time-of-day dosing exists” (ER 392); marker_2_target/marker_3_target keep the “no target / track own baseline” framing (ER 476–477).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy stays in the Contraindications (stop) gate, matching ER’s “Populations who should avoid Shatavari” (ER 358); conflicted findings are carried as “bone findings are contradicted” (time_3_sub).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from ER Key Interactions & Contraindications; Benefits only from Expected Benefits; Risks only from Potential Risks & Side Effects.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or brand names (CL22205, SheVari4, Cepham) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	The ER’s “University of Exeter” attribution is dropped rather than reassigned in action_2_sub; no new sponsor, author or institution is named.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-first register throughout, matching the ER’s own restraint about commercial funding and contradicted findings.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified doses, windows and biomarker targets are paired with plain-language framing in At-A-Glance and Qualitative Assessment.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Panels state what trials used and measured rather than instructing a course of action.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, “recommend” or “advise” appears in the document’s own voice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Cadence and monitoring cells restate the ER’s trial rhythm (ER 471) as descriptive schedule, not instruction.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun occurs anywhere in the rendered content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Every retained technical term (FSH, ALT, eGFR, hs-CRP, HbA1c) is expanded on first use, as in the ER.
2.8	Information is presented in a concise and very compact manner	🟢	Tier lines, gate items and biomarker cells are trimmed to key facts; no mechanistic rationale is carried over.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for you/your/we/our/us: no matches in content.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Nine-marker monitoring panel, lead testing and dose-range framing assume a proactive, self-quantifying reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	The 1,000 mg musculoskeletal protocol tied to an eight-week progressive resistance program presumes that willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content assumes access to hormone, liver, kidney and blood-lead panels — not general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Heavy metal contamination is carried as the single High risk, matching the ER’s point that lead exposure inverts the herb’s intended purpose for this audience (ER 266).
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Body panels use “gastrointestinal disturbance”, “bone resorption”, “contractile function”; the deliberately plain At-A-Glance wording is mandated by item 7.4 and mirrors the ER Conclusion.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fourteen fixed strings match the template byte-for-byte (QRS lines 446, 493, 541, 572, 593, 618, 643, 647–649, 794).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Normalized structural diff against core/qrs/QRS.html shows every template span present; the only additions are repeated marker_#_* rows (9) and qualitative_item_# entries (6).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit" and website="full_review" spans, the footer disclaimer and all CSS are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped by this template is empty; all four benefit tiers, all four risk tiers, both gate lists and the monitoring table are populated.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard extract dose”, “High-dose musculoskeletal protocol” and “Best time of day” are the ER’s own bold labels (ER 384, 386, 392).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Biomarker names match the ER table’s first column; protocol labels match the ER bold labels; time-to-effect labels name the three endpoints of ER 441.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	The ER’s 🟩/🟥/🟨 tier markers and ⚠️ Conflicted flags are all stripped; tiers are carried by <strong> labels and CSS palettes.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the per-section budget: parentheticals trimmed, mechanistic rationale and effect sizes removed, biomarker “Context/Notes” column dropped entirely.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The comment opens at line 2, immediately after <!doctype html> on line 1, and closes at line 14 before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	It is an HTML comment; no metadata value is echoed into <head> or <body> except the title/header values required by section 6.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: shatavari_2026-0825-0128_Opus_ER.md, matching the ER on disk.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge in core/qrs/QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0821-0252, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” = nickname plus version, no qualifier such as “[1m]”.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: shatavari_2026-0825-0128_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including git_user: evipedia-3 and git_issue: 5320; no stray whitespace or quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Shatavari for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with & encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Shatavari for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/21/2026, the correct reformat of 2026-0821-0252.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, identical to the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template subline; the ER’s “Also known as” list is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	All four sentences map to ER Conclusion paragraphs (ER 516–520): strength of evidence, strongest finding, promising-not-firm lines, funding and the lead recall.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause has a distinct source sentence in ER 516–520; no fact is invented or merged from unrelated passages.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “end of menstruation”, “heat surges”, “milk supply after birth”, “company-funded” replace menopause/vasomotor/lactation/sponsor terminology.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	The ER’s Menopause Rating Scale point changes and p-values are all omitted.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items come from the “Populations who should avoid Shatavari” list at ER 354–360.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-populations are present, none added: hormone-sensitive cancer, asparagus allergy, pregnancy, advanced CKD, under-18s.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Five <li> elements inside the stop_items span (QRS lines 575–588).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	“Pregnancy” drops the ER’s em-dash clause; the under-18 and CKD rationales are stripped; no dash-trailing clause remains in any item.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The eGFR threshold “below 30 mL/min/1.73 m²” and the allergy manifestation list are both preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s avoid-population bullets contain no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names five such populations and the section is correspondingly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map one-to-one to the ER interaction bullets at ER 334–352.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interactions are present; tamoxifen is dropped from the SERM parenthetical because it already appears in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten <li> elements inside the caution_items span (QRS lines 596–608).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Caution/Monitor” verdict, consequence and mitigation clause from the ER bullets is stripped; each item is the drug-class head plus its example list.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER parenthetical survives in shortened form; none is dropped entirely (e.g. “warfarin, digoxin”; “ibuprofen, aspirin, omeprazole”; “soy isoflavones, red clover, black cohosh”).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheticals are plain comma-separated drug lists with no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten interactions and the section is correspondingly populated, not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action sets come from ER Therapeutic Protocol (ER 384, 386, 392).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard dose, the high-dose musculoskeletal alternative and timing are the three decisions a user must make; half-life, sex, age and genotype bullets are all “unstudied/no change” and carry no action.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol lists twelve bullets, well above three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells carry ER-derived content; no placeholder token remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s Practical Considerations time-to-effect bullet (ER 441) names exactly three windows — lactation, menopausal symptoms, muscle and bone — and all three are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Menopausal symptoms (ER High tier) first, then lactation and muscle/bone (both Medium tier).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated; subs trace to ER 441, 404 and 186/245.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All thirteen items are the ER Expected Benefits sub-headings (ER 156–232), in ER order.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (QRS lines 543, 546, 553, 560).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare benefit heading; the ER’s “⚠️ Conflicted” qualifiers and all Magnitude paragraphs are dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits tier.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have ER items (1 High, 4 Medium, 4 Low, 4 Speculative).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight items are the ER Potential Risks & Side Effects sub-headings (ER 262–310), in ER order.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (QRS lines 620, 623, 626, 632).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare risk heading; the “⚠️ Conflicted” flag on reproductive-hormone shifts and all Magnitude data are dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks tier; the ER’s 15% and 11.4%-vs-8.5% rates are omitted.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have ER items (1 High, 1 Medium, 3 Low, 3 Speculative).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER Monitoring Protocol & Defining Success biomarker table (ER 473–483).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER rows present in ER order: blood lead, estradiol, FSH, ALT, eGFR, hs-CRP, HbA1c, TSH/free T3, prolactin.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS 786–787 condenses ER 469–471: baseline, symptom score at 4 and 8 weeks, panels at 12 weeks then every 6–12 months, blood lead annually.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	The six items come from the ER’s “Qualitative markers worth tracking alongside the labs” list (ER 487–492).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present in ER order, with trailing rationale clauses trimmed.

Issues 21/08/2026 03:34

Pass rate 100.00%. No issues found.

Issues 21/08/2026 03:27

1. 1.3 — ALT rationale inverts ER framing: [marker_4_why] (line 702) reads “Liver injury is seen with some Ayurvedic products”, whereas the ER row states “Confirms the absence of liver injury seen with some Ayurvedic products” (ER line 478) and the ER Risks preamble records unchanged liver panels across trials (ER line 260).
2. 9.2 — Tamoxifen duplicated across gates: “tamoxifen” appears in [caution_items] item 7 (line 604) although “current use of tamoxifen” is already an absolute contraindication in [stop_items] item 1 (line 577), so the same drug is presented as both a hard stop and a caution.

Fixes 21/08/2026 03:27

1. 1.3 — ALT rationale restored to ER framing: [marker_4_why] changed from “Liver injury is seen with some Ayurvedic products” to “Confirms the absence of liver injury seen with some Ayurvedic products”, matching the ER biomarker table verbatim.
2. 9.2 — Tamoxifen removed from Key Interactions: The SERM parenthetical in [caution_items] item 7 was reduced from “(tamoxifen, raloxifene)” to “(raloxifene)”, since current tamoxifen use is already an absolute contraindication in [stop_items].

Issues 21/08/2026 03:21

1. 7.2 — At-A-Glance exceeds 60 words: The at_a_glance span (lines 433–439) contains 61 words, one over the hard 60-word limit.

Fixes 21/08/2026 03:21

1. 7.2 — At-A-Glance trimmed under 60 words: Condensed “a narrow but real body of controlled human evidence” to “a narrow but real controlled human evidence base” and “relief of symptoms” to “symptom relief”, bringing the span from 61 to 59 words.

Issues 21/08/2026 03:16

1. 4.2 — Interaction label word order reversed: The fourth Key Interactions item (line 599) reads “Narrow-therapeutic-index and delayed-release oral drugs” whereas the ER’s bold label at line 340 is “Delayed-release and narrow-therapeutic-index oral drugs”; the label must be carried verbatim.

Fixes 21/08/2026 03:16

1. 4.2 — Interaction label word order restored: Key Interactions item 4 changed from “Narrow-therapeutic-index and delayed-release oral drugs (warfarin, digoxin)” to “Delayed-release and narrow-therapeutic-index oral drugs (warfarin, digoxin)”, matching the ER’s bold label verbatim.

Issues 21/08/2026 03:08

1. 4.5 — Sheet overflows one A4 page: The QRS carries roughly 5,400 characters of visible text, about 1.5× what this layout fits on one A4 page; the Key Interactions column (lines 594–612), several monitoring “Why” and “Target” cells, and the qualitative items retain uncondensed ER wording instead of being cut to the per-section budget.
2. 11.4 — Time-to-effect subs restate their cells: time_2_sub (line 518) and time_3_sub (line 530) paraphrase their own label and value back in prose and add no information beyond what the label and value already state.

Fixes 21/08/2026 03:08

1. 11.4 — Time-to-effect subs rewritten: time_2_sub changed from “Lactation effects appear within 72 hours” to “Postpartum trials dosed 300 mg twice daily over this window”, and time_3_sub from “Muscle and bone endpoints required six to twenty-four weeks” to “Only alongside progressive resistance training; bone findings are contradicted”, so neither restates its own label and value.
2. 4.5 — Key Interactions column condensed: Trimmed the three longest gate items — the narrow-therapeutic-index entry to “(warfarin, digoxin)”, the over-the-counter entry to “(ibuprofen, aspirin, omeprazole)”, and the phytoestrogen entry to “(soy isoflavones, red clover, black cohosh)” — retaining an example list on every item as item 9.5 requires.
3. 4.5 — Monitoring cells condensed: Shortened the two “No established target on shatavari; track change from own baseline” cells and the prolactin target to “No target…; track own baseline”, and tightened the FSH, ALT, HbA1c and thyroid cells (e.g. “free T3 in the upper half of the assay range” to “free T3 upper half of range”).
4. 4.5 — Qualitative rationale tails removed: Dropped the trailing rationale clauses from two qualitative items (“the urogenital symptoms that improved most consistently” and “the main reason to reduce the dose”), leaving the marker itself.

Issues 21/08/2026 02:59

1. 1.1 — At-A-Glance overstates sponsorship scope: [at_a_glance] (line 437) says “Most trials were company-funded”, while the ER limits the claim to the menopause literature (ER lines 160 and 518).
2. 12.3 — Conflicted qualifier in Benefits: “reduced bone resorption (conflicted)” (line 547) and “improved ovarian morphology in polycystic ovary syndrome (conflicted)” (line 553) add an evidence-strength qualifier that the tier already encodes.
3. 13.3 — Conflicted qualifier in Risks: “Unpredictable shifts in reproductive hormones (conflicted)” (line 631) adds an evidence-strength qualifier that the tier already encodes.

Fixes 21/08/2026 02:59

1. 1.1 — At-A-Glance sponsorship scope narrowed: Changed “Most trials were company-funded” to “Most menopause trials were company-funded” in [at_a_glance], matching the ER’s restriction of that claim to the menopause literature (still 60 words).
2. 12.3 — Conflicted qualifier removed from Benefits: Stripped “(conflicted)” from “reduced bone resorption” in [benefits_medium] and from “improved ovarian morphology in polycystic ovary syndrome” in [benefits_low].
3. 13.3 — Conflicted qualifier removed from Risks: Stripped “(conflicted)” from “Unpredictable shifts in reproductive hormones” in [risks_low].